Are you looking to develop a biologic, ADC, AOC, RDC or Bispecific? Schedule a meeting with our scientific & commercial leadership to discuss your complex biologic or bioconjugate program during DCAT Week 2025 between March 17-20. Lean how we can de-risk and expedite your program!

Abzena has two meeting room suites at the Lotte Palace Hotel #1516 & #1516.  Our team would appreciate the opportunity to schedule some time to connect on your project-specific needs and to provide you with an update on our expanded global capabilities. From antibodies (mAbs) to recombinant vaccines and bioconjugates including antibody-drug conjugates (ADCs), radioconjugates, and oligonucleotides (AOCs), our team appreciates the chance to share how Abzena can assist in moving your program forward faster to its next milestone.

Abzena attendees include:
– CEO, Matt Stober
– CSO, Dr Campbell Bunce
– CCO, Joe Principe
– SVP, Scientific Leader, Dr Petra Dieterich
– SVP, Commercial Strategy, Gavin Murdoch
– Global VP of Analytical Services, Rekha Patel
– Head of Business Development North America, Barbara Arnold
– Head of Business Development EU & Asia, Jonathan Cruickshank
– SVP, Global Marketing, Kimberly Burrell

Abzena is also the proud sponsor of the keynote presentation entitled, “What’s on the Horizon: New Modalities & Promising Drug Classes” and the educational session entitled, “Achieving Supply Chain Resiliency Amid Geopolitical Risk”

Educational Session: Achieving Supply Chain Resiliency Amid Geopolitical Risk

Employing effective strategies to evaluate and mitigate risk is crucial to assure supply and build resiliency in supply chains. This becomes even more challenging with an ever-changing external environment, where geopolitical and other unforeseen events, come into play. This program will feature an executive panel to share fresh insight, best practices, and lessons learned on how to best prepare, monitor, and respond to potential or actual disruption due to geopolitical events and other macro environmental factors.

This program will provide:

• Perspectives from leading companies within and outside the industry
• Collaborative approaches taken between customers and suppliers to mitigate risk
• Strategies for effective scenario planning and response

Keynote: What’s on the Horizon: New Modalities & Promising Drug Classes

A Special One-on-One Interview with a World Renowned Pioneer in GLP-1 Agonists

Glucagon-like peptide (GLP-1) agonists have taken the industry by storm with an unprecedented ascent and earning them a place among the industry’s blockbusters. How did this highly successful class of drugs come to fruition, what other opportunities exist, and what may be the next rising stars in the industry?

To answer those all-important questions, DCAT is honored to host Dr. Richard DiMarchi, Ph.D., a globally renowned researcher and former Group Vice President at Eli Lilly and Company and Novo Nordisk, who is widely recognized for his pioneering work that laid the foundation for the development of GLP-1 agonists.

Co-recipient of the 2024 Mani L. Bhaumik Breakthrough of the Year Award by the American Association for the Advancement of Science, former decade-long Chairman of the Peptide Therapeutics Foundation, co-founder of eight successful biotech companies, and a widely recognized international authority on macromolecular medicines, Dr. DiMarchi will sit down for a one-on-one interview to share the development journey of GLP-1 agonists and his perspectives on the future of drug development with a focus on:

• What new drug classes show the greatest promise and why?
• How will new modalities, such as RNA therapeutics, cell & gene therapies, and other complex drugs factor into the industry’s pipeline and commercialization strategies?
• What are the challenges and opportunities?
• What place will traditional modalities—small molecules, monoclonal antibodies, or recombinant proteins—hold in the industry’s portfolios of the future?
• Is a re-balancing act in store?

We look forward to connecting with you at DCAT 2025. Please use the form below to schedule a meeting with our team.

About Abzena

Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. We have research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.

Why Abzena?